ATARA Biotherapeutics (ATRA) Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive MS in Late-Breaking e-Poster at EAN

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/9/2026

1. USO
2. SPY
3. AMZN
4. FLUT
5. GNK
6. AVGO
7. TMUS
8. PENG
9. DFH
10. AAPL

Go back to ATARA Biotherapeutics (ATRA) Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive MS in Late-Breaking e-Poster at EAN

Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late-Breaking e-Poster at th

May 26, 2020 7:00 AM EDT

Sustained Disability Improvements Seen at Six Months Were Maintained at 12 Months with ATA188

Potential Therapeutic Response with ATA188 Supports Role of Epstein-Barr Virus (EBV) in Pathogenesis of MS

Conference Call and Webcast Today, May 26, 2020 at 8:00 a.m. EDT/2:00 p.m. CEST

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--... More